ABBVIE CDR (CAD HEDGED)ABBVIE CDR (CAD HEDGED)ABBVIE CDR (CAD HEDGED)

ABBVIE CDR (CAD HEDGED)

No trades
See on Supercharts
Market capitalization
‪437.54 B‬CAD
1.49CAD
‪6.51 B‬CAD
‪73.31 B‬CAD
Beta (1Y)
Employees (FY)
‪50 K‬
Change (1Y)
0
Revenue / Employee (1Y)
‪1.11 M‬CAD
Net income / Employee (1Y)
‪98.17 K‬CAD

About AbbVie Inc.


CEO
Robert A. Michael
Headquarters
North Chicago
Website
Founded
2011
FIGI
BBG01BPHQ821
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
A
ACT4176286
Allergan Funding SCS 4.85% 15-JUN-2044
Yield to maturity
7.40%
Maturity date
Jun 15, 2044
A
A5QD
ALLERGAN FNDG 15/25
Yield to maturity
7.36%
Maturity date
Mar 15, 2025
A
ACT4218883
Allergan Funding SCS 4.75% 15-MAR-2045
Yield to maturity
7.28%
Maturity date
Mar 15, 2045
A
ACT4218882
Allergan Funding SCS 4.55% 15-MAR-2035
Yield to maturity
7.17%
Maturity date
Mar 15, 2035
A
ACT3910526
Actavis, Inc. 4.625% 01-OCT-2042
Yield to maturity
7.06%
Maturity date
Oct 1, 2042
ABBV4911706
AbbVie Inc. 3.2% 21-NOV-2029
Yield to maturity
6.00%
Maturity date
Nov 21, 2029
ABBV5068388
AbbVie Inc. 4.625% 01-OCT-2042
Yield to maturity
5.76%
Maturity date
Oct 1, 2042
US287YAW9
ABBVIE 16/46
Yield to maturity
5.75%
Maturity date
May 14, 2046
ABBV5068387
AbbVie Inc. 4.25% 21-NOV-2049
Yield to maturity
5.74%
Maturity date
Nov 21, 2049
ABBV4036937
AbbVie Inc. 4.4% 06-NOV-2042
Yield to maturity
5.73%
Maturity date
Nov 6, 2042
ABBV5068389
AbbVie Inc. 4.85% 15-JUN-2044
Yield to maturity
5.71%
Maturity date
Jun 15, 2044

Explore more bonds 

Frequently Asked Questions


The current price of ABBV is 25.62 CAD — it has increased by 3.18% in the past 24 hours. Watch ABBVIE CDR (CAD HEDGED) stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NEO exchange ABBVIE CDR (CAD HEDGED) stocks are traded under the ticker ABBV.
ABBV stock has risen by 4.90% compared to the previous week, the month change is a −6.07% fall, over the last year ABBVIE CDR (CAD HEDGED) has showed a 25.65% increase.
ABBV reached its all-time high on Oct 31, 2024 with the price of 30.02 CAD, and its all-time low was 19.45 CAD and was reached on Jun 28, 2023. View more price dynamics on ABBV chart.
See other stocks reaching their highest and lowest prices.
Today ABBVIE CDR (CAD HEDGED) has the market capitalization of ‪45.36 B‬, it has increased by 3.24% over the last week.
Yes, you can track ABBVIE CDR (CAD HEDGED) financials in yearly and quarterly reports right on TradingView.
ABBV net income for the last quarter is ‪2.12 B‬ CAD, while the quarter before that showed ‪1.86 B‬ CAD of net income which accounts for 13.69% change. Track more ABBVIE CDR (CAD HEDGED) financial stats to get the full picture.
No, ABBV doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has ‪50.00 K‬ employees. See our rating of the largest employees — is ABBVIE CDR (CAD HEDGED) on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. ABBVIE CDR (CAD HEDGED) EBITDA is ‪34.48 B‬ CAD, and current EBITDA margin is 49.30%. See more stats in ABBVIE CDR (CAD HEDGED) financial statements.
Like other stocks, ABBV shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ABBVIE CDR (CAD HEDGED) stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ABBVIE CDR (CAD HEDGED) technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ABBVIE CDR (CAD HEDGED) stock shows the neutral signal. See more of ABBVIE CDR (CAD HEDGED) technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.